Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies

被引:54
作者
Andreoli, Laura [1 ,2 ]
Fredi, Micaela [1 ,2 ,3 ]
Nalli, Cecilia [1 ,2 ,3 ]
Piantoni, Silvia [1 ,2 ,3 ]
Reggia, Rossella [1 ,2 ,3 ]
Dall'Ara, Francesca [1 ,2 ,3 ]
Franceschini, Franco
Tincani, Angela [1 ,2 ]
机构
[1] Spedali Civil Brescia, Dept Clin & Expt Sci, I-25123 Brescia, Italy
[2] Univ Brescia, I-25123 Brescia, Italy
[3] Univ Pavia, Rheumatol Chair, I-27100 Pavia, Italy
关键词
Anti-phospholipid antibodies; Anti-cardiolipin antibodies; Anti-beta 2glycoprotein I antibodies; Lupus anticoagulant; IgA antibodies; Thrombosis; Pregnancy loss; Stroke; Primary antiphospholipid syndrome; Systemic lupus erythematosus; Pathogenic anti-phospholipid antibodies; Domains of beta 2glycoprotein I; Classification criteria; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTIPHOSPHOLIPID HUGHES SYNDROME; RECURRENT SPONTANEOUS-ABORTION; 13TH INTERNATIONAL-CONGRESS; HENOCH-SCHONLEIN PURPURA; INDEPENDENT RISK-FACTOR; BETA 2-GLYCOPROTEIN I; ANTI-BETA(2)-GLYCOPROTEIN I; GLYCOPROTEIN-I; CLASSIFICATION CRITERIA;
D O I
10.1007/s11926-013-0343-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IgA antiphospholipid antibodies (aPL) are not currently recognized as formal laboratory criteria for the Antiphospholipid Syndrome (APS). This is mainly due to methodological issues (different study designs, use of various non-standardized IgA assays). However, there are experimental data showing the pathogenic role of IgA anticardiolipin antibodies (aCL) and IgA anti-beta 2glycoprotein I antibodies (anti-beta 2GPI). Isolated IgA aCL are not very common, therefore their testing could be useful in the case of strong suspicion of APS but negative results for other aPL tests. IgA anti-beta 2GPI seem to be the most prevalent isotype in patients with Systemic Lupus Erythematosus (SLE), with a significant association with thrombotic events. Such a clinical relevance has been recently recognized by the inclusion of these autoantibodies among the aPL tests in the novel SLICC classification criteria for SLE. Emerging interest has been raised by IgA anti-beta 2GPI against domain 4/5 as a novel subgroup of clinically relevant aPL.
引用
收藏
页数:8
相关论文
共 70 条
[1]   Catastrophic antiphospholipid syndrome associated with anti-beta-2-glycoprotein I IgA [J].
Abinader, A ;
Hanly, AJ ;
Lozada, CJ .
RHEUMATOLOGY, 1999, 38 (01) :84-85
[2]  
Akhter E, 2010, ARTHRITIS RHEUM, V62, pS5
[3]   ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE ANALYSIS OF 500 CONSECUTIVE PATIENTS [J].
ALARCONSEGOVIA, D ;
DELEZE, M ;
ORIA, CV ;
SANCHEZGUERRERO, J ;
GOMEZPACHECO, L ;
CABIEDES, J ;
FERNANDEZ, L ;
DELEON, SP .
MEDICINE, 1989, 68 (06) :353-365
[4]  
Bernardini I, 2009, SCHOLARY RES EXCHANG, P1
[5]   'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010 [J].
Bertolaccini, M. L. ;
Amengual, O. ;
Atsumi, T. ;
Binder, W. L. ;
de laat, B. ;
Forastiero, R. ;
Kutteh, W. H. ;
Lambert, M. ;
Matsubayashi, H. ;
Murthy, V. ;
Petri, M. ;
Rand, J. H. ;
Sanmarco, M. ;
Tebo, A. E. ;
Pierangeli, S. S. .
LUPUS, 2011, 20 (02) :191-205
[6]  
Bertolaccini ML, 2001, J RHEUMATOL, V28, P2637
[7]   Independent Association of Anti-β2-Glycoprotein I Antibodies With Macrovascular Disease and Mortality in Scleroderma Patients [J].
Boin, Francesco ;
Franchini, Stefano ;
Colantuoni, Elizabeth ;
Rosen, Antony ;
Wigley, Fredrick M. ;
Casciola-Rosen, Livia .
ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2480-2489
[8]  
Bruce IN, 2000, J RHEUMATOL, V27, P2833
[9]   IgA class anticardiolipin antibodies in cutaneous leukocytoclastic vasculitis [J].
Burden, AD ;
Tillman, DM ;
Foley, P ;
Holme, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 35 (03) :411-415
[10]   Value of IgA anticardiolipin and anti-β2-glycoprotein I antibody testing in patients with pregnancy morbidity [J].
Carmo-Pereira, S ;
Bertolaccini, ML ;
Escudero-Contreras, A ;
Khamashta, MA ;
Hughes, GRV .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (06) :540-543